pharma Β· Asthma Β· Osteoarthritis Β· AMRX
Amneal Pharma Europe
Amneal Pharma Europe Ltd
Amneal Pharma Europe patent portfolio β 32 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 400 Crossing Boulevard, Bridgewater, New Jersey 08807, US
- Founded
- 2002
- Employees
- 7,179
- Programs
- 15
- Drugs
- 210
- Patents
- 32
Amneal Pharma Europe patents
32 pharmaceutical patents indexed for Amneal Pharma Europe. 0 expire within 24 months.
Amneal Pharma Europe has 32 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β use filters for patent-cliff planning.
Patent portfolio
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted -
US 12201596
Levodopa dosing regimen
granted -
US 12194150
Levodopa dosing regimen
granted -
US 12109185
Levodopa dosing regimen
granted -
US 12011502
Compositions and methods of administering baclofen
granted -
US 11986449
Levodopa dosing regimen
granted -
US 11931328
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
granted -
US 11911515
Extended release compositions comprising pyridostigmine
granted -
US 11850225
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 11666536
Extended release compositions comprising pyridostigmine
granted -
US 11654124
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
granted -
US 11564888
Extended release compositions comprising trihexyphenidyl
granted -
US 11547670
Delayed release methylphenidate compositions
granted -
US 11523984
Compositions and methods of administering baclofen
granted -
US 11491125
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 11478425
Extended release compositions comprising pyridostigmine
granted -
US 11439585
Programmable pharmaceutical compositions for chrono drug release
granted -
US 11318091
Gastroretentive dosage forms for sustained drug delivery
granted -
US 11229606
Extended release compositions comprising pyridostigmine
granted -
US 11179320
Self-regulating osmotic gastroretentive drug delivery systems
granted -
US 11166906
Programmable pharmaceutical compositions for chrono drug release
granted -
US 11154494
Programmable pharmaceutical compositions for chrono drug release
granted -
US 10052467
Applicator for applying a fluid to a surface
granted -
US 9629805
Stabilization of moisture-sensitive drugs
granted -
US 9227044
Applicator for applying a fluid to a surface
granted
Frequently asked questions
How many patents does Amneal Pharma Europe have?
32 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Amneal Pharma Europe patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.